ERBB2 and breast cancer: These findings are of prognostic importance as breast cancer survival is known to vary by tumor subtype, with the highest five-year relative survival reported for patients with HR+/HER2− (92%), followed by HR+/HER2+ (89%), HR−/HER2+ (83%), and TN (77%) [30].